SeekingAlphaSeptember 7, 2026 at 10:08 PM NYLast Month
Underestimating The Moat: Why McKesson's Oncology Pivot And Share Buybacks Signal Structural Upside
McKesson operates within a US pharma distribution oligopoly, generating $5B+ in FCF and aggressively repurchasing shares. See why I rate MCK stock a Buy.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: SeekingAlpha
